CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Probody® therapeutics are antibody prodrugs designed to be activated by tumor-associated proteases. This conditional activation restricts antibody binding to the tumor microenvironment, thereby minimizing ‘off-tumor’ toxicity. Here, we report the phase 1 data from the first-in-human study of CX-072 (pacmilimab), a Probody immune checkpoint inhibitor directed against programmed death-ligand 1 (PD-L1), in combination with the anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab. Methods: Adults (n=27) with advanced solid tumors (naive to PD-L1/programmed cell death protein 1 or CTLA-4 inhibitors) were enrolled in the phase 1 combination therapy dose-escalation portion of this multicenter, open-label, phase 1/2 study (NCT03013491). Dose-escalation pacmilimab/ipilimumab followed a standard 3+3 design and continued until the maximum tolerated dose (MTD) was determined. Pacmilimab+ipilimumab was administered intravenously every 3 weeks for four cycles, followed by pacmilimab administered every 2 weeks as monotherapy. The primary objective was identification of dose-limiting toxicities and determination of the MTD. Other endpoints included the rate of objective response (Response Evaluation Criteria In Solid Tumors v.1.1). Results: Twenty-seven patients were enrolled in pacmilimab (mg/kg)+ipilimumab (mg/kg) dose-escalation cohorts: 0.3+3 (n=6); 1+3 (n=3); 3+3 (n=3); 10+3 (n=8); 10+6 (n=6); and 10+10 (n=1). Dose-limiting toxicities occurred in three patients, one at the 0.3+3 dose level (grade 3 dyspnea/pneumonitis) and two at the 10+6 dose level (grade 3 colitis, grade 3 increased aspartate aminotransferase). The MTD and recommended phase 2 dose was pacmilimab 10 mg/kg+ipilimumab 3 mg/kg administered every 3 weeks. Pacmilimab-related grade 3–4 adverse events (AEs) and grade 3–4 immune-related AEs were reported in nine (33%) and six (22%) patients, respectively. Three patients (11%) discontinued treatment because of AEs. The overall response rate was 19% (95% CI 6.3 to 38.1), with one complete (anal squamous cell carcinoma) and four partial responses (cancer of unknown primary, leiomyosarcoma, mesothelioma, testicular cancer). Responses lasted for >12 months in four patients. Conclusions: The MTD and recommended phase 2 dose of pacmilimab (10 mg/kg)+ipilimumab (3 mg/kg) every 3 weeks is active and has a favorable tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The first in-human study of CX-072 (pacmilimab), a probody ICI targeting PD-L1, combined with the anti-CTLA-4 antibody ipilimumab, examined 27 patients reporting a tolerable profile at a recommended phase 2 dose of 10 mg/kg as well as preliminary efficacy with an overall response rate of 19%, including one testicular cancer patient who had a partial response which was durable for >12 months [78].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,196
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 733
Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.6212 · Cited by 624
Self-citationBaxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 578
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
Desnoyers, L. R., Vasiljeva, O., Richardson, J. H., Yang, A., Menendez, E. E. M., Liang, T. W., Wong, C., Bessette, P. H., Kamath, K., Moore, S. J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006682 · Cited by 281 · cited 1×
“14 15 17 Over 90% of tumors across different indications, stages, and treatment histories demonstrated sufficient protease activity to enable cleavage of the linker peptide, ensuring that Probody therapeutics would be active in various tumor microenvironments (data not shown).”
Long, G. V., Atkinson, V., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 245
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 243
Autio, K. A., Boni, V., Humphrey, R. W., & Naing, A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1457 · Cited by 184
Self-citationFeng, Y., Roy, A., Masson, E., Chen, T.-T., Humphrey, R., & Weber, J. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3243 · Cited by 183 · cited 1×
“12 It is therefore possible that ipilim-umab dose reduction or discontinuation compromises clinical efficacy.”
Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
Feng, Y., Masson, E., Dai, D., Parker, S. M., Berman, D., & Roy, A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12323 · Cited by 103
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
Adaptation of the Immune Related Response Criteria: Irrecist
Bohnsack, O., Hoos, A., & Ludajic, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.23 · Cited by 95
Probody therapeutics for targeting antibodies to diseased tissue
Polu, K. R., & Lowman, H. B. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920814 · Cited by 84 · cited 1×
“13 16 They consist of the antibody backbone and a masking peptide held in place by a protease-cleavable linker peptide.”
Schmidt, E. V., Chisamore, M. J., Chaney, M. F., Maradeo, M. E., Anderson, J., Baltus, G. A., Pinheiro, E. M., & Uebele, V. N. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20833 · Cited by 58
Yang, Y., Jin, G., Pang, Y., Huang, Y., Wang, W., Zhang, H., Tuo, G., Wu, P., Wang, Z., & Zhu, Z. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00040 · Cited by 57
Naing, A., Thistlethwaite, F. C., de Vries, E. G. E., Eskens, F. A. L. M., Uboha, N. V., Ott, P. A., LoRusso, P. M., García-Corbacho, J., Boni, V., Bendell, J. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002447 · Cited by 57
Self-citationGiesen, D., Broer, L. N., Hooge, M. N. L., Popova, I., Howng, B., Nguyen, M. T. L., Vasiljeva, O. S., de Vries, E. G. E., & Pool, M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3137 · Cited by 54
Vasiljeva, O. S., Hostetter, D. R., Moore, S. J., & Winter, M. B. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0451 · Cited by 53
Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes
Vasiljeva, O. S., Menendez, E., Nguyen, M. T. L., Craik, C. S., & Kavanaugh, W. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-62339-7 · Cited by 39
Model‐Informed Drug Development of the Masked Anti‑PD‑L1 Antibody CX‐072
Stroh, M., GREEN, M. L., Millard, B. L., Apgar, J. F., Burke, J. M., Garner, W., Lu, H., Lyman, S. K., Desnoyers, L., Richardson, J. H., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1985 · Cited by 18
Self-citationLyman, S. K., Naing, A., Zein, I. A., Howng, B., Winter, M. B., Vasiljeva, O. S., Garner, W., Zheng, B., Stroh, M., Kavanaugh, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3108 · Cited by 10
Self-citation
Cited by
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 115
Naing, A., Thistlethwaite, F. C., de Vries, E. G. E., Eskens, F. A. L. M., Uboha, N. V., Ott, P. A., LoRusso, P. M., García-Corbacho, J., Boni, V., Bendell, J. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002447 · Cited by 57
Self-citationde Ruijter, L. K., Hooiveld-Noeken, J. S., Giesen, D., Hooge, M. N. L., Kok, I. C., Brouwers, A. H., Elias, S. G., Nguyen, M. T. L., Lu, H., Gietema, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0453 · Cited by 50
“agent or in combination with ipilimumab has shown durable objective responses in patients with advanced solid tumors (11, 12).”
BackgroundExploiting protease activation for therapy
Bleuez, C., Koch, W. F., Urbach, C., Hollfelder, F., & Jermutus, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.011 · Cited by 47
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症:英文版 · doi:10.1002/cac2.12587 · Cited by 44
Metadata
- Authors
- Sanborn, R. E., Hamid, O., de Vries, E. G., Ott, P. A., Garcia-Corbacho, J., Boni, V., Bendell, J., Autio, K. A., Cho, D. C., Plummer, R., Stroh, M., Lu, L., & Thistlethwaite, F.
- Affiliations
- Department of Medical Oncology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA
- Angeles Clinic and Research Institute (US)
- Department of Medical Oncology, Universitair Medisch Centrum Groningen, University of Groningen, Groningen, Netherlands
- Dana-Farber Cancer Institute (US)
- Department of Medical Oncology, Hospital Clinic Barcelona/IDIBAPS, Barcelona, Spain
- Hospital Universitario HM Sanchinarro (ES)
- Sarah Cannon (US)
- Memorial Sloan Kettering Cancer Center (US)
- NYU Langone Health (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- CytomX Therapeutics (United States) (US)
- University of Manchester (GB)
- Corresponding author
- Sanborn, Rachel E
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2021-07
- Volume
- 9
- Issue
- 7
- Pages
- e002446
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC8311331
- OpenAlex
- W3184123570
- Cited by
- 28
- References
- 30
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 4
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- CytomX Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- PD-L1 inhibitors, ipilimumab, CTLA-4 inhibitors, immune checkpoint inhibitors, combination immunotherapy, advanced solid tumors, dose-limiting toxicity, maximum tolerated dose, pneumonitis, colitis, objective response rate, tumor-associated proteases
- MeSH terms
- Ipilimumab, Immune Checkpoint Inhibitors, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Female, Humans, Immunotherapy, Male, Middle Aged, Neoplasms, Prodrugs, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.